You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRasagiline
Accession NumberDB01367  (EXPT02758)
TypeSmall Molecule
GroupsApproved
DescriptionRasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Structure
Thumb
Synonyms
(1R)-N-Propargylindan-1-amine
(R)-Indan-1-yl-prop-2-ynyl-amine
(R)-N-2-Propynyl-1-indanamine
RAS
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Azilecttablet1 mg/1oralPhysicians Total Care, Inc.2010-12-03Not applicableUs
Azilecttablet1.0 mgoralTeva Pharmaceutical Industries Ltd2006-09-14Not applicableCanada
Azilecttablet.5 mg/1oralTeva Neuroscience, Inc.2006-07-10Not applicableUs
Azilecttablet1 mg/1oralTeva Neuroscience, Inc.2006-07-10Not applicableUs
Azilecttablet0.5 mgoralTeva Pharmaceutical Industries Ltd2006-09-14Not applicableCanada
Rasagiline RatiopharmTablet1 mgOral useTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOral useTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOral useTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOral useTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOral useTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOral useTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOral useTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOral useTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOral useTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOral useTeva B.V.2015-01-12Not applicableEu
Teva-rasagilinetablet0.5 mgoralTeva Canada Limited2016-05-30Not applicableCanada
Teva-rasagilinetablet1 mgoralTeva Canada Limited2016-05-30Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-rasagilinetablet0.5 mgoralApotex Inc2016-01-12Not applicableCanada
Apo-rasagilinetablet1 mgoralApotex Inc2016-01-12Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Rasagiline mesylate
ThumbNot applicableDBSALT001384
Categories
UNII003N66TS6T
CAS number136236-51-6
WeightAverage: 171.2383
Monoisotopic: 171.104799421
Chemical FormulaC12H13N
InChI KeyInChIKey=RUOKEQAAGRXIBM-GFCCVEGCSA-N
InChI
InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1
IUPAC Name
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
SMILES
C#CCN[C@@H]1CCC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassIndanes
Sub ClassNot Available
Direct ParentIndanes
Alternative Parents
Substituents
  • Indane
  • Aralkylamine
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
PharmacodynamicsRasagiline is a propargylamine and an irreversible inhibitor of monoamine oxidase (MAO). MAO, a flavin-containing enzyme, regulates the metabolic degradation of catecholamines and serotonin in the CNS and peripheral tissues. It is classified into two major molecular species, A and B, and is localized in mitochondrial membranes throughout the body in nerve terminals, brain, liver and intestinal mucosa. MAO-A is found predominantly in the GI tract and liver, and regulates the metabolic degradation of circulating catecholamines and dietary amines. MAO-B is the major form in the human brain and is responsible for the regulation of the metabolic degradation of dopamine and phenylethylamine. In ex vivo animal studies in brain, liver and intestinal tissues rasagiline was shown to be a potent,selective, and irreversible monoamine oxidase type B (MAO-B) inhibitor. At the recommended therapeutic doses, Rasagiline was also shown to be a potent and irreversible inhibitor of MAO-B in platelets. The selectivity of rasagiline for inhibiting only MAO-B (and not MAO-A) in humans and the sensitivity to tyramine during rasagiline treatment at any dose has not been sufficiently characterized to avoid restriction of dietary tyramine and amines contained in medications.
Mechanism of actionThe precise mechanisms of action of rasagiline is unknown. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline's beneficial effects seen in models of dopaminergic motor dysfunction.
Related Articles
AbsorptionRasagiline is rapidly absorbed following oral administration. The absolute bioavailability of rasagiline is about 36%.
Volume of distribution
  • 87 L
Protein bindingPlasma protein binding ranges from 88-94% with mean extent of binding of 61-63% to human albumin over the concentration range of 1-100 ng/ml.
Metabolism

Rasagiline undergoes almost complete biotransformation in the liver prior to excretion. In vitro experiments indicate that both routes of rasagiline metabolism are dependent on the cytochrome P450 (CYP) system, with CYP 1A2 being the major isoenzyme involved in rasagiline metabolism.

Route of eliminationRasagiline undergoes almost complete biotransformation in the liver prior to excretion. Glucuronide conjugation of rasagiline and its metabolites, with subsequent urinary excretion, is the major elimination pathway. After oral administration of 14C-labeled rasagiline, elimination occurred primarily via urine and secondarily via feces (62% of total dose in urine and 7% of total dose in feces over 7 days), with a total calculated recovery of 84% of the dose over a period of 38 days. Less than 1% of rasagiline was excreted as unchanged drug in urine.
Half lifeRasagiline has a mean steady-state half life of 3 hours but there is no correlation of pharmacokinetics with its pharmacological effect because of its irreversible inhibition of MAO-B.
ClearanceNot Available
ToxicitySigns and symptoms of overdosage may include, alone or in combination, any of the following: drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions, and coma; rapid and irregular pulse, hypertension, hypotension and vascular collapse; precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9901
Blood Brain Barrier+0.9782
Caco-2 permeable+0.5585
P-glycoprotein substrateNon-substrate0.661
P-glycoprotein inhibitor INon-inhibitor0.7409
P-glycoprotein inhibitor IINon-inhibitor0.7116
Renal organic cation transporterNon-inhibitor0.5584
CYP450 2C9 substrateNon-substrate0.8037
CYP450 2D6 substrateSubstrate0.5724
CYP450 3A4 substrateNon-substrate0.6928
CYP450 1A2 substrateInhibitor0.9037
CYP450 2C9 inhibitorNon-inhibitor0.8259
CYP450 2D6 inhibitorInhibitor0.6769
CYP450 2C19 inhibitorInhibitor0.5689
CYP450 3A4 inhibitorNon-inhibitor0.8542
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.534
Ames testNon AMES toxic0.6468
CarcinogenicityNon-carcinogens0.8959
BiodegradationNot ready biodegradable0.6073
Rat acute toxicity2.8164 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7804
hERG inhibition (predictor II)Non-inhibitor0.7137
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral1 mg
Tabletoral.5 mg/1
Tabletoral0.5 mg
Tabletoral1 mg/1
Tabletoral1.0 mg
TabletOral use1 mg
Prices
Unit descriptionCostUnit
Azilect 0.5 mg tablet12.11USD tablet
Azilect 1 mg tablet12.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2031714 No1998-08-252010-12-06Canada
CA2232310 No2008-01-082016-09-18Canada
US5387612 No1995-02-072012-02-07Us
US5453446 No1997-02-072017-02-07Us
US6126968 No1996-09-182016-09-18Us
US7572834 No2006-12-052026-12-05Us
US7815942 No2007-08-272027-08-27Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0249 mg/mLALOGPS
logP2.26ALOGPS
logP2.3ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)8.69ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity54.47 m3·mol-1ChemAxon
Polarizability20.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Jeffrey Sterling, David Lerner, Harel Rosen, Leonid Bronov, Dalia Medini-Green, Berta Iosefzon, Tirtsah Berger-Peskin, Ramy Lidor-Hadas, Eliezer Bahar, “Rasagiline formulations and processes for their preparation.” U.S. Patent US07598420, issued October 06, 2009.

US07598420
General References
  1. Weinreb O, Amit T, Bar-Am O, Youdim MB: Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol. 2010 Nov;92(3):330-44. doi: 10.1016/j.pneurobio.2010.06.008. Epub 2010 Jun 19. [PubMed:20600573 ]
  2. Leegwater-Kim J, Bortan E: The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging. 2010 May 25;5:149-56. [PubMed:20517484 ]
  3. Chen JJ, Swope DM, Dashtipour K: Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 Sep;29(9):1825-49. [PubMed:18035186 ]
External Links
ATC CodesN04BD02
AHFS Codes
  • 28:92.00
PDB Entries
FDA labelDownload (200 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineRasagiline may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineRasagiline may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.
AbirateroneThe serum concentration of Rasagiline can be increased when it is combined with Abiraterone.
AcarboseRasagiline may increase the hypoglycemic activities of Acarbose.
AcebutololRasagiline may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Aceprometazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Acetophenazine.
AlbiglutideRasagiline may increase the hypoglycemic activities of Albiglutide.
AliskirenRasagiline may increase the hypotensive activities of Aliskiren.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Rasagiline.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Rasagiline.
AlogliptinRasagiline may increase the hypoglycemic activities of Alogliptin.
AlprenololRasagiline may increase the hypotensive activities of Alprenolol.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Rasagiline.
AmbrisentanRasagiline may increase the hypotensive activities of Ambrisentan.
AmineptineRasagiline may increase the serotonergic activities of Amineptine.
AmisulprideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Amisulpride.
AmitriptylineRasagiline may increase the serotonergic activities of Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Rasagiline.
AmlodipineRasagiline may increase the hypotensive activities of Amlodipine.
AmoxapineRasagiline may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Rasagiline.
AmperozideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Amperozide.
AmphetamineRasagiline may increase the hypertensive activities of Amphetamine.
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Rasagiline.
ApraclonidineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Apraclonidine.
ArbutamineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Arformoterol.
AripiprazoleThe risk or severity of adverse effects can be increased when Rasagiline is combined with Aripiprazole.
AsenapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Asenapine.
AtenololRasagiline may increase the hypotensive activities of Atenolol.
AtomoxetineRasagiline may increase the central neurotoxic activities of Atomoxetine.
AtropineRasagiline may increase the hypertensive activities of Atropine.
AzaperoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Azaperone.
AzithromycinThe metabolism of Rasagiline can be decreased when combined with Azithromycin.
BambuterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bambuterol.
BenazeprilRasagiline may increase the hypotensive activities of Benazepril.
BendroflumethiazideRasagiline may increase the hypotensive activities of Bendroflumethiazide.
BenzphetamineRasagiline may increase the hypertensive activities of Benzphetamine.
BepridilRasagiline may increase the hypotensive activities of Bepridil.
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Rasagiline.
BetaxololRasagiline may increase the hypotensive activities of Betaxolol.
BethanidineRasagiline may increase the hypotensive activities of Bethanidine.
BezafibrateThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bezafibrate.
BifeprunoxThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bifeprunox.
BimatoprostRasagiline may increase the hypotensive activities of Bimatoprost.
BisoprololRasagiline may increase the hypotensive activities of Bisoprolol.
BortezomibThe metabolism of Rasagiline can be decreased when combined with Bortezomib.
BosentanRasagiline may increase the hypotensive activities of Bosentan.
BretyliumRasagiline may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Rasagiline is combined with Brexpiprazole.
BrimonidineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Brimonidine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rasagiline.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Rasagiline.
BupranololRasagiline may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Rasagiline.
BupropionRasagiline may increase the hypertensive activities of Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Rasagiline.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Rasagiline.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Rasagiline.
CaffeineThe metabolism of Rasagiline can be decreased when combined with Caffeine.
CanagliflozinRasagiline may increase the hypoglycemic activities of Canagliflozin.
CandesartanRasagiline may increase the hypotensive activities of Candesartan.
CandoxatrilRasagiline may increase the hypotensive activities of Candoxatril.
CaptoprilRasagiline may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Rasagiline.
CariprazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Cariprazine.
CarteololRasagiline may increase the hypotensive activities of Carteolol.
CarvedilolRasagiline may increase the hypotensive activities of Carvedilol.
CeliprololRasagiline may increase the hypotensive activities of Celiprolol.
ChlorothiazideRasagiline may increase the hypotensive activities of Chlorothiazide.
ChlorphentermineRasagiline may increase the hypertensive activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Chlorpromazine.
ChlorpropamideRasagiline may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Chlorprothixene.
ChlorthalidoneRasagiline may increase the hypotensive activities of Chlorthalidone.
CilazaprilRasagiline may increase the hypotensive activities of Cilazapril.
CirazolineRasagiline may increase the hypertensive activities of Cirazoline.
CitalopramRasagiline may increase the serotonergic activities of Citalopram.
CitalopramThe metabolism of Rasagiline can be decreased when combined with Citalopram.
ClemastineRasagiline may increase the anticholinergic activities of Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clenbuterol.
ClomipramineRasagiline may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Rasagiline.
ClonidineRasagiline may increase the hypotensive activities of Clonidine.
ClotrimazoleThe metabolism of Rasagiline can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clozapine.
CryptenamineRasagiline may increase the hypotensive activities of Cryptenamine.
CyamemazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Cyamemazine.
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Rasagiline.
CyclothiazideRasagiline may increase the hypotensive activities of Cyclothiazide.
CyproheptadineRasagiline may increase the anticholinergic activities of Cyproheptadine.
Cyproterone acetateThe serum concentration of Rasagiline can be decreased when it is combined with Cyproterone acetate.
DapagliflozinRasagiline may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Rasagiline.
DapoxetineRasagiline may increase the serotonergic activities of Dapoxetine.
DebrisoquinRasagiline may increase the hypotensive activities of Debrisoquin.
DeferasiroxThe serum concentration of Rasagiline can be increased when it is combined with Deferasirox.
DeserpidineRasagiline may increase the hypotensive activities of Deserpidine.
DesipramineRasagiline may increase the serotonergic activities of Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Rasagiline.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Rasagiline.
DesvenlafaxineRasagiline may increase the serotonergic activities of Desvenlafaxine.
DexmethylphenidateRasagiline may increase the hypertensive activities of Dexmethylphenidate.
DextroamphetamineRasagiline may increase the hypertensive activities of Dextroamphetamine.
DextromethorphanRasagiline may increase the serotonergic activities of Dextromethorphan.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Rasagiline.
DiazoxideRasagiline may increase the hypotensive activities of Diazoxide.
DiethylpropionRasagiline may increase the hypertensive activities of Diethylpropion.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Rasagiline.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Rasagiline.
DiltiazemRasagiline may increase the hypotensive activities of Diltiazem.
DipivefrinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dipivefrin.
DisopyramideRasagiline may increase the hypoglycemic activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dobutamine.
DolasetronDolasetron may increase the serotonergic activities of Rasagiline.
DomperidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Domperidone.
DorzolamideRasagiline may increase the hypotensive activities of Dorzolamide.
DosulepinRasagiline may increase the serotonergic activities of Dosulepin.
DoxapramRasagiline may increase the hypertensive activities of Doxapram.
DoxazosinRasagiline may increase the hypotensive activities of Doxazosin.
DoxepinRasagiline may increase the serotonergic activities of Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Rasagiline.
DoxylamineRasagiline may increase the anticholinergic activities of Doxylamine.
DroperidolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Droperidol.
DroxidopaThe risk or severity of adverse effects can be increased when Rasagiline is combined with Droxidopa.
DulaglutideRasagiline may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Rasagiline.
DuloxetineRasagiline may increase the serotonergic activities of Duloxetine.
EfonidipineRasagiline may increase the hypotensive activities of Efonidipine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Rasagiline.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Rasagiline.
EmpagliflozinRasagiline may increase the hypoglycemic activities of Empagliflozin.
EnalaprilRasagiline may increase the hypotensive activities of Enalapril.
EnalaprilatRasagiline may increase the hypotensive activities of Enalaprilat.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Rasagiline.
EphedraThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ephedra.
EpinephrineRasagiline may increase the hypertensive activities of Epinephrine.
EpoprostenolRasagiline may increase the hypotensive activities of Epoprostenol.
EprosartanRasagiline may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Rasagiline.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Rasagiline.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Rasagiline.
ErgotamineRasagiline may increase the hypertensive activities of Ergotamine.
EscitalopramRasagiline may increase the serotonergic activities of Escitalopram.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Rasagiline.
EsmirtazapineRasagiline may increase the serotonergic activities of Esmirtazapine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Rasagiline.
EtoperidoneRasagiline may increase the serotonergic activities of Etoperidone.
ExenatideRasagiline may increase the hypoglycemic activities of Exenatide.
FelodipineRasagiline may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fencamfamine.
FenfluramineRasagiline may increase the serotonergic activities of Fenfluramine.
FenoldopamRasagiline may increase the hypotensive activities of Fenoldopam.
FenoterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fenoterol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Rasagiline.
FluoxetineRasagiline may increase the serotonergic activities of Fluoxetine.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Rasagiline.
FlupentixolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fluspirilene.
FluvoxamineThe serum concentration of Rasagiline can be increased when it is combined with Fluvoxamine.
FluvoxamineRasagiline may increase the serotonergic activities of Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Formoterol.
FosinoprilRasagiline may increase the hypotensive activities of Fosinopril.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Rasagiline.
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Rasagiline.
GliclazideRasagiline may increase the hypoglycemic activities of Gliclazide.
GlimepirideRasagiline may increase the hypoglycemic activities of Glimepiride.
GlipizideRasagiline may increase the hypoglycemic activities of Glipizide.
GlyburideRasagiline may increase the hypoglycemic activities of Glyburide.
GranisetronGranisetron may increase the serotonergic activities of Rasagiline.
GuanabenzRasagiline may increase the hypotensive activities of Guanabenz.
GuanadrelRasagiline may increase the hypotensive activities of Guanadrel.
GuanethidineRasagiline may increase the hypotensive activities of Guanethidine.
GuanfacineRasagiline may increase the hypotensive activities of Guanfacine.
HaloperidolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Haloperidol.
HexamethoniumRasagiline may increase the hypotensive activities of Hexamethonium.
HydralazineRasagiline may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideRasagiline may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Hydrocodone.
HydroflumethiazideRasagiline may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideRasagiline may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.
IloperidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Iloperidone.
ImipramineRasagiline may increase the serotonergic activities of Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Rasagiline.
IndacaterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Indacaterol.
IndalpineRasagiline may increase the serotonergic activities of Indalpine.
IndapamideRasagiline may increase the hypotensive activities of Indapamide.
IndenololRasagiline may increase the hypotensive activities of Indenolol.
IndoraminRasagiline may increase the hypotensive activities of Indoramin.
Insulin AspartRasagiline may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirRasagiline may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineRasagiline may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineRasagiline may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanRasagiline may increase the hypoglycemic activities of Insulin Human.
Insulin LisproRasagiline may increase the hypoglycemic activities of Insulin Lispro.
IrbesartanRasagiline may increase the hypotensive activities of Irbesartan.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Rasagiline.
IsoetarineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isoetarine.
IsomethepteneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isometheptene.
IsoprenalineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isoprenaline.
IsradipineRasagiline may increase the hypotensive activities of Isradipine.
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Rasagiline.
LabetalolRasagiline may increase the hypotensive activities of Labetalol.
LacidipineRasagiline may increase the hypotensive activities of Lacidipine.
LanreotideRasagiline may increase the hypoglycemic activities of Lanreotide.
LatanoprostRasagiline may increase the hypotensive activities of Latanoprost.
LercanidipineRasagiline may increase the hypotensive activities of Lercanidipine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Rasagiline.
LevomilnacipranRasagiline may increase the serotonergic activities of Levomilnacipran.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Rasagiline.
LevonordefrinRasagiline may increase the hypertensive activities of Levonordefrin.
LidocaineThe metabolism of Rasagiline can be decreased when combined with Lidocaine.
LinezolidThe risk or severity of adverse effects can be increased when Rasagiline is combined with Linezolid.
LiraglutideRasagiline may increase the hypoglycemic activities of Liraglutide.
LisdexamfetamineRasagiline may increase the hypertensive activities of Lisdexamfetamine.
LisinoprilRasagiline may increase the hypotensive activities of Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Rasagiline.
LithiumThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lithium.
LofexidineRasagiline may increase the hypotensive activities of Lofexidine.
LorcaserinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lorcaserin.
LosartanRasagiline may increase the hypotensive activities of Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Loxapine.
Lu AA21004Rasagiline may increase the serotonergic activities of Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lurasidone.
MacitentanRasagiline may increase the hypotensive activities of Macitentan.
ManidipineRasagiline may increase the hypotensive activities of Manidipine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Rasagiline.
MecamylamineRasagiline may increase the hypotensive activities of Mecamylamine.
MecaserminRasagiline may increase the hypoglycemic activities of Mecasermin.
MelperoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Melperone.
MephentermineRasagiline may increase the hypertensive activities of Mephentermine.
MequitazineRasagiline may increase the anticholinergic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Mesoridazine.
MetaraminolRasagiline may increase the hypertensive activities of Metaraminol.
MetforminRasagiline may increase the hypoglycemic activities of Metformin.
MethadoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methadone.
MethamphetamineRasagiline may increase the hypertensive activities of Methamphetamine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methotrimeprazine.
MethoxamineRasagiline may increase the hypertensive activities of Methoxamine.
MethyldopaThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methyldopa.
Methylene blueRasagiline may increase the serotonergic activities of Methylene blue.
MethylphenidateRasagiline may increase the hypertensive activities of Methylphenidate.
MetipranololRasagiline may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Metoclopramide.
MetolazoneRasagiline may increase the hypotensive activities of Metolazone.
MetoprololRasagiline may increase the hypotensive activities of Metoprolol.
MexiletineThe serum concentration of Rasagiline can be increased when it is combined with Mexiletine.
MianserinRasagiline may increase the neurotoxic activities of Mianserin.
MibefradilRasagiline may increase the hypotensive activities of Mibefradil.
MidodrineRasagiline may increase the hypertensive activities of Midodrine.
MifepristoneRasagiline may increase the hypoglycemic activities of Mifepristone.
MiglitolRasagiline may increase the hypoglycemic activities of Miglitol.
MilnacipranRasagiline may increase the serotonergic activities of Milnacipran.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Rasagiline.
MinoxidilRasagiline may increase the hypotensive activities of Minoxidil.
MirtazapineRasagiline may increase the central neurotoxic activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Rasagiline.
MoclobemideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Moclobemide.
MoexiprilRasagiline may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Morphine.
MoxonidineRasagiline may increase the hypotensive activities of Moxonidine.
NadololRasagiline may increase the hypotensive activities of Nadolol.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Rasagiline.
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Rasagiline.
NateglinideRasagiline may increase the hypoglycemic activities of Nateglinide.
NebivololRasagiline may increase the hypotensive activities of Nebivolol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Rasagiline.
NevirapineThe metabolism of Rasagiline can be decreased when combined with Nevirapine.
NicardipineRasagiline may increase the hypotensive activities of Nicardipine.
NicorandilRasagiline may increase the hypotensive activities of Nicorandil.
NiguldipineRasagiline may increase the hypotensive activities of Niguldipine.
NilvadipineRasagiline may increase the hypotensive activities of Nilvadipine.
NimodipineRasagiline may increase the hypotensive activities of Nimodipine.
NisoldipineRasagiline may increase the hypotensive activities of Nisoldipine.
NitrendipineRasagiline may increase the hypotensive activities of Nitrendipine.
NitroprussideRasagiline may increase the hypotensive activities of Nitroprusside.
NorepinephrineRasagiline may increase the hypertensive activities of Norepinephrine.
NortriptylineRasagiline may increase the serotonergic activities of Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Rasagiline.
OctreotideRasagiline may increase the hypoglycemic activities of Octreotide.
OlanzapineRasagiline may increase the serotonergic activities of Olanzapine.
OlmesartanRasagiline may increase the hypotensive activities of Olmesartan.
OlodaterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Olodaterol.
OmapatrilatRasagiline may increase the hypotensive activities of Omapatrilat.
OndansetronThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Rasagiline.
OrciprenalineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Orciprenaline.
OsanetantThe risk or severity of adverse effects can be increased when Rasagiline is combined with Osanetant.
OsimertinibThe serum concentration of Rasagiline can be decreased when it is combined with Osimertinib.
OxprenololRasagiline may increase the hypotensive activities of Oxprenolol.
OxycodoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Rasagiline.
PaliperidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Rasagiline.
PargylineRasagiline may increase the hypotensive activities of Pargyline.
ParoxetineRasagiline may increase the serotonergic activities of Paroxetine.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Rasagiline.
PasireotideRasagiline may increase the hypoglycemic activities of Pasireotide.
Peginterferon alfa-2bThe serum concentration of Rasagiline can be increased when it is combined with Peginterferon alfa-2b.
PenbutololRasagiline may increase the hypotensive activities of Penbutolol.
PentamidineRasagiline may increase the hypoglycemic activities of Pentamidine.
PentoliniumRasagiline may increase the hypotensive activities of Pentolinium.
PergolideThe metabolism of Pergolide can be decreased when combined with Rasagiline.
PerindoprilRasagiline may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Rasagiline is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Perphenazine.
PethidineRasagiline may increase the serotonergic activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Rasagiline.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Rasagiline.
PhenobarbitalThe metabolism of Rasagiline can be increased when combined with Phenobarbital.
PhenoxybenzamineRasagiline may increase the hypotensive activities of Phenoxybenzamine.
PhentermineRasagiline may increase the hypertensive activities of Phentermine.
PhentolamineRasagiline may increase the hypotensive activities of Phentolamine.
PhenylephrineRasagiline may increase the hypertensive activities of Phenylephrine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Phenylpropanolamine.
PholcodinePholcodine may increase the serotonergic activities of Rasagiline.
PimozideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pimozide.
PinacidilRasagiline may increase the hypotensive activities of Pinacidil.
PindololRasagiline may increase the hypotensive activities of Pindolol.
PioglitazoneRasagiline may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pirbuterol.
PizotifenRasagiline may increase the anticholinergic activities of Pizotifen.
PolythiazideRasagiline may increase the hypotensive activities of Polythiazide.
PramlintideRasagiline may increase the hypoglycemic activities of Pramlintide.
PrazosinRasagiline may increase the hypotensive activities of Prazosin.
PrimidoneThe metabolism of Rasagiline can be increased when combined with Primidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Rasagiline.
ProcaterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Rasagiline.
PropericiazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Propericiazine.
PropranololRasagiline may increase the hypotensive activities of Propranolol.
ProtriptylineRasagiline may increase the serotonergic activities of Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Rasagiline.
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Rasagiline.
QuetiapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Quetiapine.
QuinaprilRasagiline may increase the hypotensive activities of Quinapril.
QuinineRasagiline may increase the hypoglycemic activities of Quinine.
RamiprilRasagiline may increase the hypotensive activities of Ramipril.
RemikirenRasagiline may increase the hypotensive activities of Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Remoxipride.
RepaglinideRasagiline may increase the hypoglycemic activities of Repaglinide.
RescinnamineRasagiline may increase the hypotensive activities of Rescinnamine.
ReserpineRasagiline may increase the hypotensive activities of Reserpine.
RifampicinThe metabolism of Rasagiline can be increased when combined with Rifampicin.
RiociguatRasagiline may increase the hypotensive activities of Riociguat.
RisperidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Risperidone.
RitodrineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ritodrine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Rasagiline.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Rasagiline.
RopiniroleThe metabolism of Rasagiline can be decreased when combined with Ropinirole.
RosiglitazoneRasagiline may increase the hypoglycemic activities of Rosiglitazone.
SalbutamolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Salmeterol.
SaprisartanRasagiline may increase the hypotensive activities of Saprisartan.
SaxagliptinRasagiline may increase the hypoglycemic activities of Saxagliptin.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Rasagiline.
SelexipagRasagiline may increase the hypotensive activities of Selexipag.
SertindoleThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sertindole.
SertralineRasagiline may increase the serotonergic activities of Sertraline.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Rasagiline.
SimeprevirThe metabolism of Rasagiline can be decreased when combined with Simeprevir.
SitagliptinRasagiline may increase the hypoglycemic activities of Sitagliptin.
SitaxentanRasagiline may increase the hypotensive activities of Sitaxentan.
SpiraprilRasagiline may increase the hypotensive activities of Spirapril.
SulfadiazineRasagiline may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleRasagiline may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleRasagiline may increase the hypoglycemic activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Rasagiline.
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Rasagiline.
SunitinibRasagiline may increase the hypoglycemic activities of Sunitinib.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Rasagiline.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Rasagiline.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tedizolid Phosphate.
TelmisartanRasagiline may increase the hypotensive activities of Telmisartan.
TemocaprilRasagiline may increase the hypotensive activities of Temocapril.
TenofovirThe metabolism of Rasagiline can be decreased when combined with Tenofovir.
TerbutalineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Terbutaline.
TeriflunomideThe serum concentration of Rasagiline can be decreased when it is combined with Teriflunomide.
TerlipressinRasagiline may increase the hypotensive activities of Terlipressin.
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Rasagiline.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Rasagiline.
TetryzolineRasagiline may increase the hypertensive activities of Tetryzoline.
TheophyllineThe metabolism of Rasagiline can be decreased when combined with Theophylline.
ThioproperazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thiothixene.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Rasagiline.
TianeptineRasagiline may increase the serotonergic activities of Tianeptine.
TiboloneRasagiline may increase the hypotensive activities of Tibolone.
TiclopidineThe metabolism of Rasagiline can be decreased when combined with Ticlopidine.
TicrynafenRasagiline may increase the hypotensive activities of Ticrynafen.
TimololRasagiline may increase the hypotensive activities of Timolol.
TolazamideRasagiline may increase the hypoglycemic activities of Tolazamide.
TolazolineRasagiline may increase the hypotensive activities of Tolazoline.
TolbutamideRasagiline may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Rasagiline.
TorasemideRasagiline may increase the hypotensive activities of Torasemide.
TramadolTramadol may increase the neuroexcitatory activities of Rasagiline.
TramadolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tramadol.
TrandolaprilRasagiline may increase the hypotensive activities of Trandolapril.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Rasagiline.
TravoprostRasagiline may increase the hypotensive activities of Travoprost.
TrazodoneRasagiline may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Rasagiline.
TreprostinilRasagiline may increase the hypotensive activities of Treprostinil.
TrichlormethiazideRasagiline may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Triflupromazine.
TrimazosinRasagiline may increase the hypotensive activities of Trimazosin.
TrimethaphanRasagiline may increase the hypotensive activities of Trimethaphan.
TrimipramineRasagiline may increase the serotonergic activities of Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Rasagiline.
UnoprostoneRasagiline may increase the hypotensive activities of Unoprostone.
ValsartanRasagiline may increase the hypotensive activities of Valsartan.
VemurafenibThe serum concentration of Rasagiline can be increased when it is combined with Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Rasagiline.
VenlafaxineRasagiline may increase the serotonergic activities of Venlafaxine.
VilanterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Vilanterol.
VilazodoneRasagiline may increase the serotonergic activities of Vilazodone.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Rasagiline.
VortioxetineRasagiline may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Rasagiline.
XylometazolineRasagiline may increase the hypotensive activities of Xylometazoline.
ZimelidineRasagiline may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Rasagiline.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Rasagiline.
ZotepineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol and caffeine.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Naoi M, Maruyama W: Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev Neurother. 2009 Aug;9(8):1233-50. doi: 10.1586/ern.09.68. [PubMed:19673610 ]
  2. Uzun M, Alp R, Uzlu E, Alp S, Citil M, Topcu B, Erdogan HM: Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):95-8. [PubMed:19499843 ]
  3. Youdim MB, Weinstock M: Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol. 2001 Dec;21(6):555-73. [PubMed:12043833 ]
  4. Chau KY, Cooper JM, Schapira AH: Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. Neurochem Int. 2010 Nov;57(5):525-9. doi: 10.1016/j.neuint.2010.06.017. Epub 2010 Jul 17. [PubMed:20624440 ]
  5. Weinreb O, Amit T, Bar-Am O, Youdim MB: Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol. 2010 Nov;92(3):330-44. doi: 10.1016/j.pneurobio.2010.06.008. Epub 2010 Jun 19. [PubMed:20600573 ]
  6. Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T: Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005 Jan 1-15;79(1-2):172-9. [PubMed:15573406 ]
  7. Leegwater-Kim J, Bortan E: The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging. 2010 May 25;5:149-56. [PubMed:20517484 ]
  8. Chen JJ, Swope DM, Dashtipour K: Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 Sep;29(9):1825-49. [PubMed:18035186 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
activator
General Function:
Ubiquitin protein ligase binding
Specific Function:
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating f...
Gene Name:
BCL2
Uniprot ID:
P10415
Molecular Weight:
26265.66 Da
References
  1. Youdim MB, Weinstock M: Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol. 2001 Dec;21(6):555-73. [PubMed:12043833 ]
  2. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M: An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002 Jun 28;326(2):105-8. [PubMed:12057839 ]
  3. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M: Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002 Sep-Oct;24(5):675-82. [PubMed:12200198 ]
  4. Youdim MB, Amit T, Falach-Yogev M, Bar Am O, Maruyama W, Naoi M: The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol. 2003 Oct 15;66(8):1635-41. [PubMed:14555244 ]
  5. Bar-Am O, Weinreb O, Amit T, Youdim MB: Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 2005 Nov;19(13):1899-901. Epub 2005 Sep 7. [PubMed:16148027 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Lecht S, Haroutiunian S, Hoffman A, Lazarovici P: Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy. Ther Clin Risk Manag. 2007 Jun;3(3):467-74. [PubMed:18488080 ]
  2. Leegwater-Kim J, Bortan E: The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging. 2010 May 25;5:149-56. [PubMed:20517484 ]
  3. Chen JJ, Swope DM, Dashtipour K: Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 Sep;29(9):1825-49. [PubMed:18035186 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 02:26